Markers predicting response to complement inhibitor therapy
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of generalized myasthenia gravis and test positive for anti-AChR antibodies.
- Your doctor has recommended complement inhibitor therapy according to approved guidelines.
- You are able to attend follow-up visits at the study center.
- You are willing and able to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
This study looks for markers that might predict who will respond well to a new class of medicines called FcRn inhibitors. These medicines help reduce harmful antibodies that attack nerves and muscles in people with a certain type of Myasthenia Gravis. The goal is to better personalize treatment for patients in Italy.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Hear when a new Myasthenia Gravis, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.